Actively Recruiting
Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
Led by University of California, Los Angeles · Updated on 2026-03-04
50
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of continuous glucose monitoring (CGM) shortly after delivery to predict the long-term risk of developing Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes. This pilot study focuses on how well CGM works compared to standard tests like the 2-hour glucose tolerance test and HbA1c test postpartum. The study is sponsored by the University of California, Los Angeles and aims to gather detailed blood sugar data to improve risk assessment. Participants will receive a continuous glucose monitor within two hours after delivery and will wear it for 24 hours to collect detailed blood sugar information. After 24 hours, participants will be asked to remove the device themselves. The study includes completing two surveys about their experience with the CGM device at 1 to 3 months postpartum and again at 12 to 14 months postpartum. During the study, researchers will compare CGM data collected immediately postpartum to traditional glucose tests taken later. They will also assess patient satisfaction with the CGM device during follow-up surveys. The total participation involves wearing the device for one day after delivery and completing surveys over the following year. The study will monitor clinical efficacy and patient experience to understand CGM's potential role in predicting diabetes risk after gestational diabetes.
CONDITIONS
Brief Title
Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prenatal care at UCLA Health
- Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
- Confirmed gestational diabetes diagnosis based on 2-step approach
- Maternal age 18 years or older
You will not qualify if you...
- Pre-gestational diabetes (type 1 or type 2 diabetes mellitus)
- Multifetal pregnancy
- Intra-amniotic infection by clinical criteria
- Postpartum hemorrhage
- Admission to maternal intensive care unit
- Known allergy to medical-grade adhesive
- Skin lesions at the CGM application site
- Scheduled postpartum imaging studies such as radiograph, MRI, or CT scan
- Use of metformin
- Use of steroids
- Use of terbutaline within 4 hours of delivery
- Diagnosis of cystic fibrosis
- Diagnosis of mature onset diabetes in the young (MODY)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 hours
Participants have a continuous glucose monitor applied within 2 hours after delivery for 24-hour collection of glycemic data.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
R
Rujuta Sathe
D
Dana Levin-Lopez, MPH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here